廣告
香港股市 將收市，收市時間：6 小時

  • 恒指

    17,217.10
    +15.83 (+0.09%)
     

  • 國指

    6,106.14
    +5.92 (+0.10%)
     

  • 上證綜指

    3,039.94
    -4.89 (-0.16%)
     

  • 滬深300

    3,511.45
    -10.17 (-0.29%)
     

  • 美元

    7.8295
    -0.0014 (-0.02%)
     

  • 人民幣

    0.9250
    +0.0003 (+0.03%)
     

  • 道指

    38,460.92
    -42.77 (-0.11%)
     

  • 標普 500

    5,071.63
    +1.08 (+0.02%)
     

  • 納指

    15,712.75
    +16.11 (+0.10%)
     

  • 日圓

    0.0501
    -0.0001 (-0.12%)
     

  • 歐元

    8.3824
    +0.0067 (+0.08%)
     

  • 英鎊

    9.7570
    0.0000 (0.00%)
     

  • 紐約期油

    82.62
    -0.19 (-0.23%)
     

  • 金價

    2,330.70
    -7.70 (-0.33%)
     

  • Bitcoin

    64,199.74
    -2,478.34 (-3.72%)
     

  • CMC Crypto 200

    1,390.39
    -33.71 (-2.37%)
     

Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics

Vandana Singh
·1 分鐘文章

Verve Therapeutics Inc (NASDAQ: VERV) entered into an amended and restated collaboration and license Agreement with Beam Therapeutics Inc (NASDAQ: BEAM), which amended the agreement initially announced in April 2019.

  • The original agreement provided Verve with an exclusive, worldwide, sublicensable license under certain of Beam’s base editing, gene editing, and delivery technologies for applications against four liver-mediated cardiovascular disease targets and two undisclosed gene targets.

  • Under the amendment, Beam granted Verve a license toward an additional liver-mediated cardiovascular disease target.

  • Verve will be responsible for developing and commercializing products targeting such genes, subject to Beam’s opt-in right.

  • Following the final dosing of a patient in the Phase 1 trial of a licensed product for such gene, Beam can opt-in to share 35% of development costs, commercializing costs, and profits.

  • If Beam does not opt-in, it would be entitled to receive milestones and royalties.

  • Verve granted Beam an exclusive license under Verve’s intellectual property, including under Verve’s GalNAc-LNP delivery technology, relating to a preclinical program developed by Verve.

  • In addition, the amended agreement grants Beam, on a target-by-target basis, the option to obtain a non-exclusive license to Verve’s GalNAc-LNP delivery technology.

  • Beam would owe Verve a fee upon exercise of each option, certain milestones, and low single-digit royalties.

  • Price Action: BEAM stock closed at $45.56, and VERV stock closed at $17.59 on Wednesday.

  •  

  •  

 

廣告

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.